Wall Street Seeks Next Pharmaceutical Success in Hair Loss Treatments
Following the enormous stock market gains from GLP-1 drugs for weight loss, Wall Street is shifting its focus to therapies for hair loss. Androgenetic alopecia affects approximately 50 million men and 30 million women in the United States, yet no new medication for this condition has been approved so far.